Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Neoplasms, Unknown Primary × Vemurafenib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Melanoma 35 Neoplasms 14 Neoplasm Metastasis 5 Thyroid Neoplasms 3 Skin Neoplasms 2 Recurrence 2 Colorectal Neoplasms 2 Wilms Tumor 1 Urinary Bladder Neoplasms 1 Thyroid cancer, follicular 1 Thyroid Cancer, Papillary 1 Skin Diseases 1 Sarcoma, Ewing 1 Sarcoma 1 Rhabdomyosarcoma 1 Rhabdoid Tumor 1 Osteosarcoma 1 Neuroectodermal Tumors, Primitive, Peripheral 1 Neuroblastoma 1 Neoplasms, Unknown Primary 1 Lymphoma, Non-Hodgkin 1 Lymphoma 1 Leukemia, Hairy Cell 1 Histiocytosis, Langerhans-Cell 1 Heterotaxy Syndrome 1 Hepatoblastoma 1 Glioma 1 Ependymoma 1 Colorectal Cancer Metastatic 1 Central Nervous System Neoplasms 1

Interventions

Carboplatin 8 Paclitaxel 7 Gemcitabine 7 Irinotecan 6 Radiotherapy 4 Oxaliplatin 4 Capecitabine 4 Leucovorin 3 Fluorouracil 3 Filgrastim 3 Cisplatin 3 etoposide phosphate 2 Trastuzumab 2 Surveys and Questionnaires 2 Peripheral Blood Stem Cell Transplantation 2 Etoposide 2 Erlotinib Hydrochloride 2 Bevacizumab 2 Amifostine 2 Albumin-Bound Paclitaxel 2 tipifarnib 1 tegafur-gimeracil-oteracil 1 sintilimab 1 pertuzumab 1 pemigatinib 1 pembrolizumab 1 olaparib 1 ivosidenib 1 ipatasertib 1 erythromycin propionate-N-acetylcysteinate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03498521 2025-11-19

CUPISCO

Hoffmann-La Roche

Phase 2 Completed

529 enrolled 16 charts

Neoplasms, Unknown Primary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡